Table of Contents

company-logo

SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

SkinBioTherapeutics Dividend Announcement

• SkinBioTherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on SkinBioTherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

SkinBioTherapeutics Dividend History

SkinBioTherapeutics Dividend Yield

SkinBioTherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing SkinBioTherapeutics stock? Use our calculator to estimate your expected dividend yield:

SkinBioTherapeutics Financial Ratios

P/E ratio-9.73
PEG ratio-102.81
P/B ratio7.69
ROE-102.20%
Payout ratio0.00%
Current ratio6.57
Quick ratio6.48
Cash Ratio5.67

SkinBioTherapeutics Dividend FAQ

Does SkinBioTherapeutics stock pay dividends?
SkinBioTherapeutics does not currently pay dividends to its shareholders.
Has SkinBioTherapeutics ever paid a dividend?
No, SkinBioTherapeutics has no a history of paying dividends to its shareholders. SkinBioTherapeutics is not known for its dividend payments.
Why doesn't SkinBioTherapeutics pay dividends?
There are several potential reasons why SkinBioTherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will SkinBioTherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While SkinBioTherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is SkinBioTherapeutics a dividend aristocrat?
SkinBioTherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is SkinBioTherapeutics a dividend king?
SkinBioTherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is SkinBioTherapeutics a dividend stock?
No, SkinBioTherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy SkinBioTherapeutics stocks?
To buy SkinBioTherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy SkinBioTherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.